Harmony Biosciences To Present WAKIX® (pitolisant) Efficacy and Safety Data at Upcoming 2021 American Psychiatric Association Annual MeetingPRNewsWire • 04/27/21
Harmony Biosciences To Present WAKIX® (Pitolisant) Data At The 2021 AAN Annual MeetingPRNewsWire • 04/12/21
Harmony Biosciences Launches Grant Program To Address Inequities In The Delivery Of Healthcare In Patients With Sleep DisordersPRNewsWire • 04/07/21
Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business UpdatesGlobeNewsWire • 03/25/21
Harmony Biosciences Hosts Summit Which Sheds Light on Impact of Sleep Disruption in Rare DiseasesPRNewsWire • 03/19/21
Harmony Biosciences Highlights Publication of WAKIX® (pitolisant) Efficacy Data in Sleep MedicinePRNewsWire • 03/17/21
Harmony Biosciences Announces Date Of Fourth Quarter And Full Year 2020 Financial ResultsPRNewsWire • 03/04/21
Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi SyndromePRNewsWire • 12/15/20
Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business UpdatesGlobeNewsWire • 11/12/20
Harmony Biosciences Appoints Mark Graf And Eric Motley To Its Board Of DirectorsPRNewsWire • 11/11/20
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With NarcolepsyPRNewsWire • 10/14/20
Harmony Biosciences Presents Efficacy And Safety Analyses For WAKIX® (pitolisant) At Virtual SLEEP 2020PRNewsWire • 08/28/20
Harmony Biosciences To Present New Data For WAKIX® (pitolisant) At SLEEP 2020 Annual MeetingPRNewsWire • 08/24/20
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO WeekSeeking Alpha • 08/23/20
Harmony Biosciences Announces Closing Of Its Upsized Initial Public Offering And Exercise In Full Of Underwriters' Option To Purchase Additional SharesPRNewsWire • 08/21/20